Board of Directors

Michel Lussier

Executive Chairman

Michel Lussier is a serial entrepreneur in MedTech, BioTech and Digital Health sharing his time between Montreal and Brussels.  After 15 foundational years at Medtronic, Michel served as CEO or C. Suite executive for a number of private and publicly listed companies such as Celyad, Volcano Corp., InControl, Novoste, and others.  Michel now dedicates his time to the coaching of young entrepreneurs within Solvay Business School,  supporting early stage companies and advising Venture Capital firms. Michel currently serves on several companies’ boards, chairman of 2.  Michel  obtained a BSEE and M.ING. degree in  Biomedical Engineering at the University of Montreal. He also holds an MBA from INSEAD.

Liliane Chamas

Oxford Science Enterprises

Liliane joined OSE in 2019 and predominantly builds and invests in early-stage companies with a strong focus on medical devices and innovations at the intersection of technology and medicine. Previously, Liliane worked in health innovation policy, diplomacy and health system strengthening roles in emerging and low-resource contexts in over 10 countries with various international organisations (WHO, PAHO, UNRWA) and national institutions (UK NHS, UK Foreign Commonwealth Office, Health Education England). Liliane received a PhD/DPhil from the University of Oxford in Human Genetics as a Rhodes Scholar.

Matthew Frohn

Longwall Venture Partners

Matthew has over twenty years’ experience as a life science venture investor. As co-founder of Longwall Venture Partners, he has been involved as investor and board director in a range of healthcare and life science technology businesses including medical devices, molecular diagnostics, drug delivery systems, discovery tools and vaccines. He has a D.Phil in Biochemistry from the University of Oxford and pre-venture experience in clinical pathology, virology and drug development.

Tim Rea

BGF

Tim Rea has been involved with Caristo since BGF’s first investment into the company in 2020 and rejoined the board in 2025. Tim launched BGF’s early-stage investment practice and established the fund as an active investor within life sciences, diagnostics and medtech in the UK. He has been investing in early-stage technology companies for more than 25 years.

Frank Cheng

Chief Executive Officer

Led multiple digital health companies during last twenty years. Held executive positions with publicly traded companies (GE, Roche, Hillrom, Stereotaxis) and led two venture-backed companies as CEO.  Most recently President & CCO of diagnostic company with autonomous AI technology that was FDA-cleared, Medicare-reimbursed, supported by a new Category 1 CPT code, and adopted around the world.

Prof. Charalambos Antoniades

Co-founder & Chief Scientific Officer

MD PhD FESC Pioneered the research on the relationship between adipose tissue and the cardiovascular system, with specific interest in non-invasive imaging of inflammation. This knowledge has been applied in a variety of diseases, ranging from cardiovascular disease to COVID-19. Deputy Head of the Division of Cardiovascular Medicine at the University of Oxford, and Chair of the British Atherosclerosis Society.

Prof. Keith Channon

Co-founder & Chief Medical Officer

Clinical interventional cardiologist and highly experienced research leader in cardiometabolic disease and risk. Professor at the University of Oxford, with expertise in healthcare innovations in the NHS through NIHR and Director of Academic Health Science Centre.

Prof. Stefan Neubauer

Co-founder & Chief Translational Officer

MD FRCP FACC FMedSci FSCMR Devoted his work to the development and application of novel imaging techniques in MRI and spectroscopy, and most recently in coronary CT. Head of the Division of Cardiovascular Medicine and Director of the Oxford Centre for Clinical Magnetic Resonance Research (OCMR) at the University of Oxford and Past President of the Society for Cardiovascular Magnetic Resonance (SCMR).